Condition: Advanced Malignant Neoplasm · Breast Cancer · Ovarian Cancer · Sponsor: AtlasMedx, Incorporated
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
This description comes directly from the study's public registry record.
Bonnie Wettersten, MS · (847) 644-9818 · clinicaltrials@atlasmedx.com
Always discuss trial participation with your own doctor first.
| University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| Johns Hopkins | Baltimore, Maryland, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04503265